Doxil

Phase 3Small molecule

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Doxil is one of 383 small molecule programs targeting Toxicity. It is currently in Phase 3.

Indications

Total Trials

Active Trials

382

Competitors

Pipeline

Status by Indication[3][1]

Indication

ToxicityActive, not recruiting

Thrombocytopenic PurpuraActive, not recruiting

LymphomaActive, not recruiting

Cutaneous T-Cell LymphomaActive, not recruiting

LeukemiaActive, not recruiting

AdenocarcinomaActive, not recruiting

Fallopian Tube CancerActive, not recruiting

Breast CancerActive, not recruiting

Prostate CancerActive, not recruiting

Ovarian CancerActive, not recruiting

ToxicityPhase 2

Active, not recruiting

Thrombocytopenic PurpuraPhase 2

Active, not recruiting

LymphomaPhase 2

Active, not recruiting

Cutaneous T-Cell LymphomaPhase 1

Active, not recruiting

LeukemiaPhase 2

Active, not recruiting

AdenocarcinomaPhase 2

Active, not recruiting

Fallopian Tube CancerPhase 3

Active, not recruiting

Breast CancerPhase 3

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Ovarian CancerPhase 1/Phase 2

Active, not recruiting

Showing 10 of 13 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Doxil

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3

7 2

Tykerb

GSK

Preclinical

80 3

Prolia

Amgen

Preclinical

14 4

Zolymbus

AbbVie

Preclinical

1 5

Recentin

NNational Cancer Institute (NCI)

Preclinical

2 6

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 7

Nubain

AAultman Health Foundation

Preclinical

1 8

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 9

Vfend

PPrism Pharmaceuticals

Preclinical

—10

Apatinib Mesylate

BBukwang Pharmaceutical

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Active, not recruiting

Soft Tissue Sarcoma

NCT04055753

Phase 2Recruiting

Breast Cancer

NCT05748834

Q4 2028

Phase 1/2Recruiting

Ovarian Cancer

NCT05610735

Clinical

Trials by Indication[1]

Breast Cancer7 trials

Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer

Completed·NNorthwestern University·Phase 1·NCT00316875·23 enrolled

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

Recruiting·SSCRI Development Innovations, LLC·Phase 2·NCT05748834·36 enrolled

Phase I/II Trial of Doxil and Hyperthermia for Breast Cancer Patients With Chest Wall Recurrence or Stage IV Disease With Locally Advanced Breast Cancer

Unknown status·NNational Center for Research Resources (NCRR)·Phase 2·NCT00006433

Show 4 more trials

Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer

Completed·RRutgers, The State University of New Jersey·Phase 2·NCT00608972·31 enrolled

A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00091442·751 enrolled

Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 1/2·NCT00237627·107 enrolled

Doxorubicin HCL Liposome Injection (DOXIL) in Combination With Abraxane in Patients With Metastatic Breast Cancer

Completed·WWest Virginia University·Phase 1/2·NCT00442260·2 enrolled

Ovarian Cancer6 trials

Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA)

Completed·NNew Mexico Cancer Research Alliance·Phase 2·NCT00945139·46 enrolled

An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00113607·672 enrolled

Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer

Completed·NNYU Langone Health·Phase 1·NCT00846612·15 enrolled

Show 3 more trials

Combination Therapy for Recurrent Ovarian Cancer

Recruiting·SSham Sunder Kakar·Phase 1/2·NCT05610735·72 enrolled

Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer

Terminated·HHoosier Cancer Research Network·Phase 1·NCT01485874·11 enrolled

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Completed·EEpicentRx, Inc.·Phase 2·NCT02489903·139 enrolled

Multiple Myeloma5 trials

Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma

Completed·OOhio State University Comprehensive Cancer Center·Phase 2·NCT00201695·12 enrolled

A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00097981·225 enrolled

Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma

Completed·UUniversity of Michigan Rogel Cancer Center·N/A·NCT00135187·30 enrolled

Show 2 more trials

Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT00116961·40 enrolled

Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 1/2·NCT00724568·74 enrolled

Lymphoma2 trials

Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00290433·55 enrolled

A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.

Unknown status·TThe Alvin and Lois Lapidus Cancer Institute·Phase 2·NCT00333008·27 enrolled

Prostate Cancer2 trials

Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC)

Completed·UUniversity of Pittsburgh·Phase 2·NCT00307294·40 enrolled

Study of Taxotere and Doxil to Treat Advanced Androgen-Independent Prostate Cancer

Completed·UUniversity of Louisville·Phase 1/2·NCT00456989·39 enrolled

10 more indications

Adenocarcinoma2 trials

Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma

Terminated·SSCRI Development Innovations, LLC·Phase 1/2·NCT01035658·22 enrolled

Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma

Terminated·VVanderbilt-Ingram Cancer Center·Phase 2·NCT00653328·15 enrolled

Bevacizumab1 trial

Doxil, Bevacizumab and Temsirolimus Trial

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00761644·200 enrolled

Cutaneous T-cell lymphoma1 trial

Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma

Completed·UUnknown Sponsor·Phase 1·NCT01902225·24 enrolled

Thrombocytopenic Purpura1 trial

Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura

Unknown status·HHematology and Oncology Specialists·Phase 2·NCT00107913·10 enrolled

Renal Cell Carcinoma1 trial

Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma

Completed·UUniversity of Pittsburgh·Phase 2·NCT00630409·5 enrolled

Toxicity1 trial

A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life

Completed·UUniversity of Kansas Medical Center·Phase 2·NCT00222105·25 enrolled

Fallopian Tube Cancer1 trial

A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01846611·581 enrolled

Leukemia1 trial

Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia

Completed·JJoseph Tuscano·Phase 2·NCT01736943·25 enrolled

Soft Tissue Sarcoma1 trial

Study to Assess TOPO2A as a Biomarker for Sensitivity to Doxorubicin/Doxil in Soft Tissue Sarcoma

Active, not recruiting·FFox Chase Cancer Center··NCT04055753·24 enrolled

Advanced Cancer1 trial

Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00500422·134 enrolled

Sources

References

[1]
ClinicalTrials.gov — 33 trial records for Doxil. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Doxil compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Doxil. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson Pharmaceutical Research & Development, L.L.C. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Doxil

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q4 2028

Trials by Indication[1]

Breast Cancer7 trials

Ovarian Cancer6 trials

Multiple Myeloma5 trials

Lymphoma2 trials

Prostate Cancer2 trials

Adenocarcinoma2 trials

Bevacizumab1 trial

Cutaneous T-cell lymphoma1 trial

Thrombocytopenic Purpura1 trial

Renal Cell Carcinoma1 trial

Toxicity1 trial

Fallopian Tube Cancer1 trial

Leukemia1 trial

Soft Tissue Sarcoma1 trial

Advanced Cancer1 trial

References

Drug Info

Quick Facts

Related News